

Solid Tumors Tumor Cancer

A study to look at how safe different doses of atezolizumab were for patients – and how this medicine was processed through the body

A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors

Trial Status
Completed

Trial Runs In
4 Countries

Trial Identifier
NCT01375842 2011-001422-23,
GO27831 PCD4989g

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This Phase I, multicenter, first-in-human, open-label, dose-escalation study will evaluate the safety, tolerability, and pharmacokinetics of atezolizumab (MPDL3280A) administered as single agent to participants with locally advanced or metastatic solid malignancies or hematologic malignancies. The study will be conducted in two cohorts: Dose-escalation cohort and Expansion cohort.

Genentech, Inc.
Sponsor

Phase 1
Phase

NCT01375842 2011-001422-23, GO27831 PCD4989g
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years

Healthy Volunteers
No

Atezolizumab is a new medicine designed to work on the immune system, and this type of medicine is known as an immunotherapy. Patients with different types of cancers received different amounts of the study medicine to find out which dose of atezolizumab was safe, and which dose could be given to patients in future studies.